Testing the effectiveness of the biological drug, Tezepelumab, in patients with coexisting allergic rhinitis and allergic asthma
Testing the effectiveness of the biological drug, Tezepelumab, in patients with coexisting allergic rhinitis and allergic asthma
测试生物药物 Tezepelumab 对同时患有过敏性鼻炎和过敏性哮喘的患者的有效性
批准号：
490921
负责人：
Davis Abigail
金额：
$1.27万
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2022
资助国家：
加拿大
项目状态：
已结题
起止时间：
2022-12-01 至 2023-12-01
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Summary (required)
Allergic rhinitis (AR), or hayfever, is a coexisting condition in up to 80% of allergic asthma (AA) patients and can result in decreased performance at work and school, poor sleep quality, and impaired cognition. AR and AA occur due to
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金
